Opyl Limited Forms Strategic Partnership with Avion.

Opyl Limited (ASX: OPL) has entered into a service level agreement with Avion, a full-service Contract Research Organisation (CRO), to enhance clinical trial design through its AI-powered TrialKey platform. This partnership strengthens Opyl’s footprint in the APAC region, following successful collaborations with other leading CROs. Under the agreement, Opyl will provide trial feasibility assessments, predictive analytics, and competitor benchmarking to support Avion’s clinical trial operations. The integration of TrialKey aims to optimise trial design, improve site selection, and enhance participant recruitment strategies. Reports will be delivered at AU$5,000 per report, with no minimum requirement. 

Opyl’s Chief Technology Officer, Damon Rasheed, emphasized the growing demand for TrialKey and its impact on advancing clinical trials. Avion’s CEO, Dr. Sam Vohra, highlighted the role of technology in improving trial efficiency and outcomes. Both companies are committed to leveraging AI-driven insights to drive more effective, data-backed clinical trial strategies, benefiting sponsors, patients, and the broader healthcare industry.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com